Trending News

Harley-Davidson (NYSE:HOG) has unveiled its 2025 motorcycle lineup, introducing two new models: the Street Glide® Ultra, a fully equipped long-haul touring model, and the Pan America® 1250 ST adventure sport motorcycle. The company has also significantly refreshed six Cruiser models with new technology and performance features, including the Low Rider® S, Low Rider® ST, Breakout®, Heritage Classic, Fat Boy®, and Street Bob®.

Each Cruiser model features a new Milwaukee-Eight® 117 powertrain and utilizes the Harley-Davidson® Softail® chassis. The Sportster® S model receives updated suspension with a 60% increase in rear wheel travel. Additionally, the company introduced four -production Custom Vehicle Operation™ (CVO™) models, including the CVO™ Street Glide®, CVO™ Road Glide®, CVO™ Road Glide® ST, and CVO™ Pan America® model.

Natera (NTRA) announced significant results from two clinical trials in colorectal cancer (CRC). The Phase III CALGB/SWOG 80702 study, involving ~1,000 patients, demonstrated that Signatera-positive patients treated with both chemotherapy and celecoxib showed a 40% improvement in overall survival compared to chemotherapy alone.

Key findings revealed that adding celecoxib to standard chemotherapy significantly improved disease-free survival (DFS) in Signatera-positive patients, with a three-year DFS of 44.1% versus 26.6%. The study also confirmed Signatera's effectiveness in predicting recurrence.

Additionally, the ALTAIR clinical trial, studying 243 Signatera-positive patients, showed promising results for stage IV CRC patients treated with Trifluridine/Tipiracil (FTD/TPI). These patients demonstrated a median DFS of 9.76 months compared to 3.96 months in the placebo group, marking a significant advancement in personalized medicine for CRC treatment.

MicroCloud Hologram (NASDAQ: HOLO) has announced breakthroughs in quantum systems research through the combination of detection fields and quantum trajectories. The company has successfully developed a method for studying quantum bits and physical interaction parameters through detection field interaction, requiring highly precise control and advanced experimental equipment.

HOLO's quantum trajectory simulation process involves determining initial quantum system states and detection field parameters, calculating their interaction, and analyzing random measurement records to understand system evolution patterns. The company's analytical method demonstrates broad applicability across different measurement strategies and input quantum states.

The research has shown superior measurement accuracy by calculating the theoretical lower bound of average discrimination error, which consistently proves lower than the average inference error across all test cases. This advancement provides more precise data and reliable results for quantum system research.

Barrick Gold (NYSE:GOLD) has demonstrated significant economic impact in Zambia through its Lumwana Mine operations. The company contributed $3.7 billion since 2019, with $887 million in 2024 alone through various economic channels. The mine achieved its copper production guidance in 2024, with 72% of its $906 million procurement spend going to Zambian suppliers.

A major expansion project is underway at Lumwana, which will double copper production to 240kt annually and create 2,500 construction jobs through 2028, plus 550 permanent positions. The project includes developing Manyama town with new housing, an industrial supplier park, and an airport expected to be operational by 2025.

Currently maintaining 99% Zambian national employment, Barrick is expanding its training facilities and implementing a Business Accelerator Programme targeting 150 SMEs. The company is also addressing power challenges through co-generation initiatives and collaborating with ZESCO to upgrade the northwestern power corridor.

Mullen Automotive (NASDAQ: MULN) reported financial results for fiscal year 2024, highlighting a challenging year for the EV industry. The company achieved significant milestones including:

- Reduced cash spend by $85.4M compared to FY2023
- Delivered 443 vehicles valued at $21M in FY2024 vs 35 vehicles ($1M) in FY2023
- Expanded dealer network from one to seven partners
- Launched Bollinger Motors B4 production with 31 trucks delivered ($4.2M revenue)
- Established three EV production lines in the U.S.

Financial results showed $1.1M in recognized revenue for FY2024 vs $0.4M in FY2023. Net loss was $471M ($1,425.6 per share). Cash position decreased to $10.7M from $155.7M year-over-year. The company announced $13M annual reduction in cash spend effective Feb 2025.

MicroStrategy (MSTR) has announced a full redemption notice for its outstanding 0.0% Convertible Senior Notes due 2027, with an aggregate principal amount of approximately $1.05 billion. The redemption is scheduled for February 24, 2025, at 100% of the principal amount plus any accrued special interest.

Prior to the redemption date, noteholders can convert their notes into MicroStrategy class A common stock at a conversion rate of 7.0234 shares per $1,000 principal amount, equivalent to a conversion price of $142.38 per share. The company has elected to satisfy all conversion obligations solely through shares of its class A common stock, with cash payments only for fractional shares.

Inogen (NASDAQ: INGN) has announced a strategic collaboration with Yuwell, a global home healthcare medical device manufacturer. The partnership includes three key components: distribution of respiratory products in the US and select territories, R&D collaboration to enhance Inogen's innovation pipeline, and expansion into the Chinese market.

As part of the agreement, Yuwell will invest $27.2 million for a 9.9% equity stake in Inogen, strengthening Inogen's balance sheet. The collaboration aims to broaden Inogen's product portfolio and global presence while accelerating its growth trajectory. The collaboration agreement is effective immediately, while the equity purchase is expected to close in Q1 2025.

Exelixis (NASDAQ: EXEL) has released results from the phase 1b/2 STELLAR-001 trial evaluating zanzalintinib alone or combined with atezolizumab in previously-treated metastatic colorectal cancer patients. The study included 107 patients randomized 1:1, with median prior therapy lines of 3.0 and 2.5 respectively.

Key findings show improved progression-free survival (PFS) and overall survival (OS) when combining the treatments, particularly in patients without liver metastases. In this subgroup, median PFS increased from 3.3 to 8.2 months, and the 6-month survival rate reached 87.8% for the combination versus 64.7% for zanzalintinib alone.

Regarding safety, Grade 3/4 treatment-related adverse events occurred in 40% of patients on zanzalintinib alone and 48% on the combination therapy. Common side effects included nausea, diarrhea, fatigue, and hypertension. The company expects data from the related STELLAR-303 trial in the second half of 2025.

VICI Properties (NYSE: VICI) has released its tax treatment details for 2024 distributions on common stock. The company paid quarterly dividends totaling $2.1100 per share throughout 2024, with payments of $0.4150 per share in the first three quarters and $0.4325 per share in the fourth quarter.

Of the total distributions, $1.5045 is classified as ordinary dividends, with $0.1730 categorized as non-dividend distributions (return of capital). The January 9, 2025 distribution of $0.4325 will be treated as a 2025 distribution for federal tax purposes. Notably, $1.5013 qualifies as Section 199A dividends, subject to the 45-day holding period requirement.